BIOMAT Database Logo BIOMAT Database Logo

[Electrophysiologic effect of intravenous propafenone in supraventricular tachycardia]. 1991

P Iturralde, and F Nunura, and L Romero, and L Colín, and J Rosado, and O Galván, and A de Micheli, and J A González Hermosillo, and J M Casanova
Departamento de Electrofisiología, Instituto Nacional de Cardiología Ignacio Chávez, México.

The electrophysiologic effects of intravenous propafenone were studied in twenty six patients with supraventricular tachycardias. Ten patients (38%) with intranodal reentrance tachycardia common type, and sixteen patients (62%) atrioventricular orthodromic reentrance tachycardia. Propafenone (2 mg/kg intravenously) given over ten minutes period caused termination of the intranodal reentrance tachycardia in 60% of the cases and 50% to the patients with atrioventricular reentrance tachycardia. The antiarrhythmic effects observed are related to the slowing of the conduction velocity and to the prolongation of the refractoriness in the AV node and accessory pathways preventing the reentrance mechanism. The reinduction of the tachycardia was possible in 46% of the patients. This effects was more significative in the group with accessory pathways (50%), and 40% of the patients with intranodal reentrance. The supraventricular tachycardia was inducible by programmed electrical stimulation in 46% of the patients. None of the patients developed side effects to the administration of the propafenone.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011405 Propafenone An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. Apo-Propafenone,Arythmol,Baxarytmon,Cuxafenon,Fenoprain,Jutanorm,Nistaken,Norfenon,Pintoform,Prolecofen,Propafenon AL,Propafenon Hexal,Propafenon Minden,Propafenone Hydrochloride,Propafenone Hydrochloride, (R)-Isomer,Propafenone Hydrochloride, (S)-Isomer,Propafenone, (+-)-Isomer,Propafenone, (R)-Isomer,Propafenone, (S)-Isomer,Propamerck,Rythmol,Rytmo-Puren,Rytmogenat,Rytmonorm,SA-79,Hydrochloride, Propafenone,SA 79,SA79
D012032 Refractory Period, Electrophysiological The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state. Period, Neurologic Refractory,Periods, Neurologic Refractory,Refractory Period, Neurologic,Tetanic Fade,Vvedenskii Inhibition,Wedensky Inhibition,Inhibition, Vvedenskii,Inhibition, Wedensky,Neurologic Refractory Period,Neurologic Refractory Periods,Neuromuscular Fade,Neuromuscular Transmission Fade,Refractory Period, Neurological,Refractory Periods, Neurologic,Electrophysiological Refractory Period,Electrophysiological Refractory Periods,Fade, Neuromuscular,Fade, Neuromuscular Transmission,Fade, Tetanic,Neurological Refractory Period,Neurological Refractory Periods,Refractory Periods, Electrophysiological,Refractory Periods, Neurological,Transmission Fade, Neuromuscular
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

P Iturralde, and F Nunura, and L Romero, and L Colín, and J Rosado, and O Galván, and A de Micheli, and J A González Hermosillo, and J M Casanova
[Electrophysiologic effect of intravenous amiodarone on patients with paroxysmal supraventricular tachycardia].
June 1985, Zhonghua nei ke za zhi,
P Iturralde, and F Nunura, and L Romero, and L Colín, and J Rosado, and O Galván, and A de Micheli, and J A González Hermosillo, and J M Casanova
Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia.
June 1987, Journal of the American College of Cardiology,
P Iturralde, and F Nunura, and L Romero, and L Colín, and J Rosado, and O Galván, and A de Micheli, and J A González Hermosillo, and J M Casanova
Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia.
August 1985, Methods and findings in experimental and clinical pharmacology,
P Iturralde, and F Nunura, and L Romero, and L Colín, and J Rosado, and O Galván, and A de Micheli, and J A González Hermosillo, and J M Casanova
[Electrophysiologic effects of intravenous propafenone].
June 1989, Zhonghua xin xue guan bing za zhi,
P Iturralde, and F Nunura, and L Romero, and L Colín, and J Rosado, and O Galván, and A de Micheli, and J A González Hermosillo, and J M Casanova
[Electrophysiologic effects and clinical efficacy of propafenone in pediatric patients with paroxysmal supraventricular reentrant tachycardia].
April 1986, Giornale italiano di cardiologia,
P Iturralde, and F Nunura, and L Romero, and L Colín, and J Rosado, and O Galván, and A de Micheli, and J A González Hermosillo, and J M Casanova
Electrophysiologic evaluation of supraventricular tachycardia.
November 1997, Cardiology clinics,
P Iturralde, and F Nunura, and L Romero, and L Colín, and J Rosado, and O Galván, and A de Micheli, and J A González Hermosillo, and J M Casanova
Paroxysmal supraventricular tachycardia: experience with propafenone.
June 1989, Angiology,
P Iturralde, and F Nunura, and L Romero, and L Colín, and J Rosado, and O Galván, and A de Micheli, and J A González Hermosillo, and J M Casanova
Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia.
May 1984, Journal of the American College of Cardiology,
P Iturralde, and F Nunura, and L Romero, and L Colín, and J Rosado, and O Galván, and A de Micheli, and J A González Hermosillo, and J M Casanova
Electrophysiologic effects and efficacy of intravenous propafenone in terminating atrioventricular reentrant tachycardia in children.
March 2001, The American journal of cardiology,
P Iturralde, and F Nunura, and L Romero, and L Colín, and J Rosado, and O Galván, and A de Micheli, and J A González Hermosillo, and J M Casanova
Electrophysiologic mechanisms in postural supraventricular tachycardia.
July 1983, American heart journal,
Copied contents to your clipboard!